Surprise genetic discovery in macular degeneration points to new treatment strategy fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Published: May 13, 2021 By Alex Keown
Akouos, Inc. – Kathy Reape was named chief development officer of Boston-based Akouos. Reape most recently served as chief medical officer at Spark Therapeutics where she oversaw clinical development, pharmacovigilance, and medical affairs activities. Reape was a key member of the team responsible for the development and commercialization of Luxturna, the first FDA-approved in vivo gene therapy approved for an inherited retinal disease caused by mutations in both copies of the RPE65 gene. Prior to Spark, Reape was senior vice president of clinical development focusing on global brands research and development at Allergan and Actavis.
CARMAT – France-based CARMAT’s board of directors is reorganizing its governance and appointed three new directors. The company tapped Florent Battistella, David Coti and John B. Hernandez as directors. Battistella founded Nisima, a holding company, which holds stakes in various firms, notably
Tubulis Appoints Christian Grøndahl as Independent Chairman to Lead Supervisory Board Tubulis today announced the appointment of Dr. Christian Grøndahl, as the inaugural Chairman of the company s Supervisory Board. As an experienced biotech executive and company founder, Dr. Grøndahl has an established track record in advancing early-stage biotech innovations and distinguished technology platforms into valuable products and medicines. His leadership will be fundamental to shaping Tubulis as it designs and moves its novel antibody-drug conjugates (ADCs) toward clinical evaluation to improve cancer treatments and further establishes itself as an up-and-coming leader in the oncology and ADC drug development field.
7 May 2021 | 07:21am
StockMarketWire.com - Syncona Ltd, a healthcare company focused on founding, building and funding a portfolio of global leaders in life science, has noted that its portfolio company, Gyroscope Therapeutics Holdings plc has postponed plans for its initial public offering in light of the current market conditions. In light of market conditions, we have decided to postpone our planned initial public offering, said Khurem Farooq, Gyroscope Therapeutics’ chief executive officer. Based on the positive feedback we have received from institutional investors on the strength of our science and investigational gene therapies, we believe it s in the best interest of our existing shareholders and employees to execute our IPO in more favourable market conditions. In the meantime, we are continuing to advance our clinical program for our investigational gene therapy, GT005, and our earlier-stage pipeline. He added.